Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: Results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT)
Penelope Hopwood, David Cameron(Corewell Health), Dana J. Lawrence(Institute of Cancer Research), Stephen R. Russell(University of Iowa), L. Johnson(Michigan State University), Peter Ellis(Oldham Council), Peter Barrett‐Lee(Velindre Cancer Centre), Emma Hall(Institute of Cancer Research), Judith M. Bliss(Institute of Cancer Research)
Cited by 7
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
A common haplotype in the complement regulatory gene factor H ( <i>HF1/CFH</i> ) predisposes individuals to age-related macular degeneration
|Proceedings of the National Academy of Sciences|2005|2k